---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-394360"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2026-09-17T20:15:12+00:00"
generated_at: "2026-09-17T20:16:19.678877+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Faeth appoints co-founder Karen Vousden to board as Class II director

## Summary
- Board expanded from 5 to 6 directors; Vousden appointed effective Sept 11, 2026, serving until 2029 annual meeting.
- Vousden, 68, is a cancer biologist, co-founded Faeth in April 2019, and leads at Francis Crick Institute since 2017.
- Also appointed to Compensation Committee; receives standard director cash retainer and option for 25,000 shares under 2026 Equity Plan.
- Option vests monthly over 3 years, with full vesting upon change in control; no family or 404(a) transactions disclosed.

## SEC filing metadata
- accession: 0001193125-26-394360
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2026-09-17T20:15:12+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/0001193125-26-394360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/d174402d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-394360
- JSON: https://secwatch.observer/filing/0001193125-26-394360.json
- Plain text: https://secwatch.observer/filing/0001193125-26-394360.txt

## Key facts
- Executive change
  Karen Vousden was appointed as Class II Director at Sensei Biotherapeutics, Inc..
  - Action: appointed
  - Role: Class II Director
  source text: On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312526394360/0001193125-26-394360-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.